Valdivia-Cerda V, Alvarez-Zavala M, Sánchez-Reyes K, Cabrera-Silva RI, Ruiz-Herrera VV, Loza-Salazar AD, et al. Prevalence and risk factors of chronic kidney disease in an HIV positive Mexican cohort. BMC Nephrol. 2021;22(1):317.

Article  PubMed  PubMed Central  Google Scholar 

Ekrikpo UE, Kengne AP, Bello AK, Effa EE, Noubiap JJ, Salako BL, et al. Chronic kidney disease in the global adult HIV-infected population: a systematic review and meta-analysis. PLoS ONE. 2018;13(4):e0195443.

Article  PubMed  PubMed Central  Google Scholar 

Wyatt CM. Kidney disease and HIV infection. Top Antivir Med. 2017;25(1):13–6.

PubMed  PubMed Central  Google Scholar 

Swanepoel CR, Atta MG, D’Agati VD, Estrella MM, Fogo AB, Naicker S, et al. Kidney disease in the setting of HIV infection: conclusions from a kidney disease: improving global outcomes (KDIGO) Controversies Conference. Kidney Int. 2018;93(3):545–59.

Article  PubMed  PubMed Central  Google Scholar 

Zimmerman AM. Peritoneal dialysis: increasing global utilization as an option for renal replacement therapy. J Glob Health 9(2):020316.

FDA. DESCOVY FDA Package Insert. 2016.

Dosing Recommendations for Drugs Used to Treat or Prevent Opportunistic Infections That Require Dosage Adjustment in Patients with Renal Insufficiency| NIH [Internet]. 2023 [cited 2023 Apr 30]. https://clinicalinfo.hiv.gov/en/guidelines/hiv-clinical-guidelines-adult-and-adolescent-opportunistic-infections/dosing-recommendations-drugs-used-full

Gilead Sciences Inc. FDA CLINICAL PHARMACOLOGY AND BIOPHARMACEUTICS REVIEW, -. SUMMARY OF BIOPHARMACEUTICAL STUDIES AND ASSOCIATED ANALYTICAL METHODS. 2014.

Podany AT, Bares SH, Havens J, Dyavar SR, O’Neill J, Lee S, et al. Plasma and intracellular pharmacokinetics of tenofovir in patients switched from tenofovir disoproxil fumarate to tenofovir alafenamide. AIDS. 2018;32(6):761–5.

Article  CAS  PubMed  Google Scholar 

Gupta SK, Post FA, Arribas JR, Eron JJ, Wohl DA, Clarke AE, et al. Renal safety of tenofovir alafenamide vs. tenofovir disoproxil fumarate: a pooled analysis of 26 clinical trials. AIDS. 2019;33(9):1455–65.

Article  CAS  PubMed  Google Scholar 

Custodio JM, Fordyce M, Garner W, Vimal M, Ling KHJ, Kearney BP, et al. Pharmacokinetics and safety of Tenofovir Alafenamide in HIV-Uninfected subjects with severe renal impairment. Antimicrob Agents Chemother. 2016;60(9):5135–40.

Article  CAS  PubMed  PubMed Central  Google Scholar 

FDA. TIVICAY FDA Package Insert. 2013.

Moltó J, Graterol F, Miranda C, Khoo S, Bancu I, Amara A, et al. Removal of Dolutegravir by Hemodialysis in HIV-Infected patients with end-stage renal disease. Antimicrob Agents Chemother. 2016;60(4):2564–6.

Article  PubMed  PubMed Central  Google Scholar 

Eron JJ, Wilkin A, Ramgopal M, Osiyemi O, McKellar M, McKellar M, et al. A daily single tablet regimen (STR) of Bictegravir/Emtricitabine/Tenofovir alafenamide (B/F/TAF) in virologically-suppressed adults living with HIV and End Stage Renal Disease on Chronic Hemodialysis. Open Forum Infect Dis. 2020;7(Suppl 1):S529–30.

Article  PubMed Central  Google Scholar 

Eron JJ, Lelievre JD, Kalayjian R, Slim J, Wurapa AK, Stephens JL et al. Safety of elvitegravir, cobicistat, emtricitabine, and tenofovir alafenamide in HIV-1-infected adults with end-stage renal disease on chronic haemodialysis: an open-label, single-arm, multicentre, phase 3b trial. Lancet HIV. 2018;S2352-3018(18)30296-0.

Aleman J, van den Berk GEL, Franssen EJF, de Fijter CWH. Tenofovir disoproxil treatment for a HIV-hepatitis B virus coinfected patient undergoing peritoneal dialysis: which dose do we need? AIDS. 2015;29(12):1579–80.

Article  PubMed  Google Scholar 

Tucker GT. Measurement of the renal clearance of drugs. Br J Clin Pharmacol. 1981;12(6):761–70.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Rowland M, Tozer TN. Clinical pharmacokinetics: concepts and applications. 3rd ed. Baltimore: Williams & Wilkins; 1995. p. 601.

Google Scholar 

Touchcalc - Programmed by Stephen Z Fadem. PD KT/V CALCULATOR [Internet]. [cited 2023 Jul 26]. http://touchcalc.com/calculators/ktv_pd

NIH. Hemodialysis dose and adequacy - national kidney and Urologic Diseases Information Clearinghouse - National Institute of Diabetes and Digestive and kidney diseases. NIH Publication No; 2009. pp. 09–4556.

Min S, Sloan L, DeJesus E, Hawkins T, McCurdy L, Song I, et al. Antiviral activity, safety, and pharmacokinetics/pharmacodynamics of dolutegravir as 10-day monotherapy in HIV-1-infected adults. AIDS. 2011;25(14):1737.

Thurman AR, Schwartz JL, Cottrell ML, Brache V, Chen BA, Cochón L et al. Safety and Pharmacokinetics of a Tenofovir Alafenamide Fumarate-Emtricitabine based Oral Antiretroviral Regimen for Prevention of HIV Acquisition in Women: A Randomized Controlled Trial. eClinicalMedicine [Internet]. 2021 Jun 1 [cited 2023 Jul 5];36. https://www.thelancet.com/journals/eclinm/article/PIIS2589-5370(21)00173-5/fulltext

Hummert P, Parsons TL, Ensign LM, Hoang T, Marzinke MA. Validation and implementation of liquid chromatographic-mass spectrometric (LC–MS) methods for the quantification of tenofovir prodrugs. J Pharm Biomed Anal. 2018;152:248–56.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Hendrix CW, Andrade A, Bumpus NN, Kashuba AD, Marzinke MA, Moore A, et al. Dose frequency ranging pharmacokinetic study of Tenofovir-Emtricitabine after directly observed dosing in healthy volunteers to establish adherence benchmarks (HPTN 066). AIDS Res Hum Retroviruses. 2016;32(1):32–43.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Dooley KE, Savic R, Gupte A, Marzinke MA, Zhang N, Edward VA, et al. Once-weekly rifapentine and isoniazid for tuberculosis prevention in patients with HIV taking dolutegravir-based antiretroviral therapy: a phase 1/2 trial. Lancet HIV. 2020;7(6):e401–9.

Article  PubMed  Google Scholar 

Kawuma AN, Wasmann RE, Sinxadi P, Sokhela SM, Chandiwana N, Venter WDF, et al. Population pharmacokinetics of tenofovir given as either tenofovir disoproxil fumarate or tenofovir alafenamide in an African population. CPT: Pharmacometrics Syst Pharmacol. 2023;12(6):821–30.

CAS  PubMed  Google Scholar 

Di Perri G. Tenofovir alafenamide (TAF) clinical pharmacology. Infez Med. 2021;29(4):526–9.

CAS  PubMed  PubMed Central  Google Scholar 

FDA. TRUVADA FDA Package Insert. 2016.

Barditch-Crovo P, Deeks SG, Collier A, Safrin S, Coakley DF, Miller M, et al. Phase I/II trial of the Pharmacokinetics, Safety, and antiretroviral activity of Tenofovir Disoproxil Fumarate in Human Immunodeficiency Virus-infected adults. Antimicrob Agents Chemother. 2001;45(10):2733–9.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Calcagno A, Gonzalez de Requena D, Simiele M, D’Avolio A, Tettoni MC, Salassa B, et al. Tenofovir plasma concentrations according to Companion drugs: a cross-sectional study of HIV-Positive patients with normal renal function. Antimicrob Agents Chemother. 2013;57(4):1840–3.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Wood BR, Pozniak AL. Dosing lamivudine or emtricitabine in renal impairment: new data confirm it’s time for updated guidance! AIDS. 2021;35(8):1305–7.

Article  PubMed  Google Scholar 

van Lunzen J, Maggiolo F, Arribas JR, Rakhmanova A, Yeni P, Young B, et al. Once daily dolutegravir (S/GSK1349572) in combination therapy in antiretroviral-naive adults with HIV: planned interim 48 week results from SPRING-1, a dose-ranging, randomised, phase 2b trial. Lancet Infect Dis. 2012;12(2):111–8.

Article  PubMed  Google Scholar 

Anderson PL, Kiser JJ, Gardner EM, Rower JE, Meditz A, Grant RM. Pharmacological considerations for tenofovir and emtricitabine to prevent HIV infection. J Antimicrob Chemother. 2011;66(2):240–50.

Article  CAS  PubMed  Google Scholar 

Seifert SM, Chen X, Meditz AL, Castillo-Mancilla JR, Gardner EM, Predhomme JA, et al. Intracellular tenofovir and Emtricitabine anabolites in Genital, rectal, and blood compartments from first dose to steady state. AIDS Res Hum Retroviruses. 2016;32(10–11):981–91.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Paff MT, Averett DR, Prus KL, Miller WH, Nelson DJ. Intracellular metabolism of (-)- and (+)-cis-5-fluoro-1-[2-(hydroxymethyl)-1,3-oxathiolan-5-yl]cytosine in HepG2 derivative 2.2.15 (subclone P5A) cells. Antimicrob Agents Chemother. 1994;38(6):1230–8.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Painter GR, Rimsky LT, Furman PA, Liotta DC, Schinazi RF, Quinn JB. Preclinical and clinical development of the anti-HIV, anti-HBV oxathiolane nucleoside analog emtricitabine. Front Viral Hepat. 2003;451–84.

Coleman JS, Diniz CP, Fuchs EJ, Marzinke MA, Aung W, Bakshi RP, et al. Interaction of Depot Medroxyprogesterone acetate and Tenofovir Disoproxil Fumarate/Emtricitabine on Peripheral Blood mononuclear cells and cervical tissue susceptibility to HIV infection and pharmacokinetics. JAIDS J Acquir Immune Defic Syndr. 2023;92(1):89.

Article  CAS  PubMed  Google Scholar 

Kidney Disease Clinic [Internet]. [cited 2023 Apr 30]. https://kidneydiseaseclinic.net/dialyzers/kidneydiseaseclinic.net

Misra M, Khanna R. Peritoneal equilibration test. UpToDate. Retreived July 3rd, 2023, from https://www.uptodate.com/contents/peritoneal-equilibration-test#:~:text=The peritoneal equilibration test (PET,peritoneal capillary blood and dialysate. In 2022.

Ueaphongsukkit T, Gatechompol S, Avihingsanon A, Surintrspanont J, Iampenkhae K, Avihingsanon Y, et al. Tenofovir alafenamide nephrotoxicity: a case report and literature review. AIDS Res Ther. 2021;18(1):53.

Article  PubMed  PubMed Central  Google Scholar 

Avihingsanon A, Sophonphan J, Thammajaruk N, Chaihong P, Burger D, Cressey TR, et al. Plasma tenofovir concentrations and proximal tubular dysfunction in HIV-Infected adults receiving tenofovir in Thailand. J AIDS Clin Res. 2015;6(7):1–7.

Article  Google Scholar 

Kunimoto Y, Ikeda H, Fujii S, Kitagawa M, Yamazaki K, Nakata H, et al. Plasma tenofovir trough concentrations are associated with renal dysfunction in Japanese patients with HIV infection: a retrospective cohort study. J Pharm Health Care Sci. 2016;2(1):22.

Article  PubMed  PubMed Central  Google Scholar